No thanks: Roche backs out of EGFR-related protein degraders in revised deal with C4
Roche and C4 Therapeutics have been collaborators since 2016, and the relationship has proved fruitful for the biotech that just went public a little …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
